Skip to main content

Search
Profile

Jane L. Burns, MD

|
Jane L. Burns, MD

Infectious Disease, Pediatrics-Inpatient, Cystic Fibrosis Research, Infectious Disease Research

On staff since October 1982

Academic Title: Professor, Pediatrics

Research Center: Center for Global Infectious Disease Research

"For a pediatrician, there is nothing better than to come to work every day in a facility that is totally geared toward children. From the giraffes who greet us at the entrance, to the phlebotomists, medical assistants, X-ray techs and nurses who work so well with kids, what we all do every day is support the lives of sick children and their families. What could be better?"

Overview

Board Certification(s)
Pediatric Infectious Diseases
Pediatrics
Medical/Professional School
University of Washington, Seattle
Residency
Pediatrics, University of Washington, Seattle
Fellowship
Pediatric Infectious Disease, University of Washington, Seattle
Clinical Interests

Cystic fibrosis microbiology, bacterial antibiotic resistance, bone and joint infections

Research Description

Investigating the bacteria that cause cystic fibrosis
Cystic fibrosis (CF) is the most common life-shortening genetic illness in Caucasians, affecting approximately 30,000 children and adults in the U.S. alone. The abnormal CFTR gene impacts many organs, including the lungs, gastrointestinal tract and endocrine system. Chronic lung infections are the most common cause of morbidity and mortality in CF and our work is focused on the bacterial organisms that cause CF lung infections, including Pseudomonas aeruginosa, Burkholderia cepacia complex and Staphylococcus aureus. Because CF lung infections are polymicrobial, our work also addresses bacterial-bacterial interactions
P. aeruginosa is the most common organism causing lung infections in CF patients of all ages (although S. aureus is most common in children). The Burns lab's work on P. aeruginosa has primarily centered on early infections and how to eradicate them. Antibiotic resistance among P. aeruginosa isolates, including prevention, detection and treatment, has also been a longstanding area of research.
B. cepacia complex infections are relatively rare among individuals with CF, but can be deadly. Improving our understanding of the pathogenesis of these infections and identifying optimal treatment strategies are key to our ability to decrease the associated morbidity and mortality in CF patients harboring B. cepacia complex. As noted above, S. aureus is the organism most frequently isolated from children with CF. For many years, S. aureus was considered a "colonizer" that did not cause severe infections. However, recent data from our laboratory and others has identified increased morbidity in children infected with both methicillin resistant S. aureus (MRSA) and small colony variant S. aureus.
The Burns lab's current projects include investigation of the pathogenesis of B. cepacia complex in CF including the role of mucoidy in Burkholderia species and the contribution of hypermutability to specific bacterial phenotypes and clinical outcomes in B. cenocepacia infections in CF. In addition, the prevalence of small colony variant S. aureus and its impact on disease progression in children is being investigated. At the same time, we are developing new methods for antimicrobial susceptibility testing in these slow-growing variants with the goal of ultimately performing a large multicenter clinical trial.

Lab URL

http://www.seattlechildrens.org/research/global-infectious-disease-research/burns-lab/

Research Focus Area

Host: Pathogen Interaction

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Best DoctorBest Doctors in America 2014 2014
Best DoctorBest Doctors in America 2013
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2008
Golden Stethoscope AwardSeattle Metropolitan magazine 2008
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine 2007
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2003 - 2006
Frederick C. Moll Prize in Pediatrics 1978
March of Dimes Fellow 1976 - 1977
WAMI Fellow 1975
Phi Beta Kappa
B.S., Magna cum laude in Biology

Publications

Pseudomonas aeruginosa in vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes.
American journal of respiratory and critical care medicine , June 2014
Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , May 2014: 13(3)296-305
Developing an international Pseudomonas aeruginosa reference panel.
MicrobiologyOpen , Dec. 2013: 2(6)1010-23
Culture-based diagnostic microbiology in cystic fibrosis: Can we simplify the complexity?
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Oct. 2013
Pulmonary exacerbations in CF patients with early lung disease.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Sept. 2013
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , Aug. 2013: 57(3)384-91
Pseudomonas aeruginosa isolates of distinct sub-genotypes exhibit similar potential of antimicrobial resistance by drugs exposure.
Antonie van Leeuwenhoek , April 2013: 103(4)797-807
Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
Journal of aerosol medicine and pulmonary drug delivery , April 2013: 26(2)69-75
Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.
Antimicrobial agents and chemotherapy , Nov. 2012: 56(11)5971-81
Progress in cystic fibrosis and the CF Therapeutics Development Network.
Thorax , Oct. 2012: 67(10)882-90
Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Sept. 2012: 11(5)456-7
Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
Pediatric pulmonology , July 2012: 47(7)641-8
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
Influenza and other respiratory viruses , May 2012: 6(3)218-23
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , Feb. 2012: 47(2)125-34
Evolution of Pseudomonas aeruginosa virulence in infected patients revealed in a Dictyostelium discoideum host model
Clin Microbiol Infect , Sept. 2011: 1415-20
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
Influenza and other respiratory viruses , Sept. 2011
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine , Sept. 2011: 165(9)847-56
Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
Journal of clinical microbiology , July 2011: 49(7)2772-3
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Pediatric pulmonology , Feb. 2011: 46(2)184-92
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.
PloS one , 2011: 6(9)e23637
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.
Journal of bacteriology , Dec. 2010: 192(23)6191-9
Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrobial agents and chemotherapy , July 2010: 54(7)3024-6
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , May 2010: 303(17)1707-15
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Pediatric pulmonology , April 2010: 45(4)363-70
Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
PLoS pathogens , Jan. 2010: 6(1)e1000712
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Antimicrobial agents and chemotherapy , Jan. 2010: 54(1)143-8
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
The Journal of antimicrobial chemotherapy , Oct. 2009: 64(4)829-36
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , May 2009: 30(3)256-68
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Jan. 2009: 8(1)66-70
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan: 8(1)66-70
Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.
Genomics , June 2008: 91(6)530-7
Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.
Genomics , 2008 Jun: 91(6)530-7
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Pediatric pulmonology , Jan. 2008: 43(1)47-58
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Pediatric pulmonology , 2008 Jan: 43(1)47-58
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
The Journal of infectious diseases , Oct. 2007: 196(7)1088-92
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
The Journal of infectious diseases , 2007 Oct 1: 196(7)1088-92
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , July 2007: 42(7)610-23
Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia.
Microbes and infection / Institut Pasteur , June 2007: 9(7)829-37
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology , June 2007: 42(6)533-41
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , 2007 Jul: 42(7)610-23
Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia.
Microbes and infection / Institut Pasteur , 2007 Jun: 9(7)829-37
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology , 2007 Jun: 42(6)533-41
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
Molecular microbiology , April 2007: 64(2)512-33
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
American journal of respiratory and critical care medicine , 2007 Apr 15: 175(8)822-8
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
Molecular microbiology , 2007 Apr: 64(2)512-33
Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis.
Journal of clinical microbiology , 2007 Feb: 45(2)529-35
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
Pediatric pulmonology , 2006 Jul: 41(7)656-65
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
Proceedings of the National Academy of Sciences of the United States of America , 2006 May 30: 103(22)8487-92
Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.
Chemical biology & drug design , 2006 Feb: 67(2)162-73
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.
The Journal of clinical investigation , 2006 Feb: 116(2)436-46
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
The Journal of antimicrobial chemotherapy , 2005 Nov: 56(5)879-86
Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia.
FEMS microbiology letters , 2005 Apr 15: 245(2)337-44
Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
Infection and immunity , 2005 Jan: 73(1)444-52
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation.
Infection and immunity , 2004 Sep: 72(9)5126-34
Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum.
Microbiology (Reading, England) , 2004 Sep: 150(Pt 9)2947-58
Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.
The Pediatric infectious disease journal , 2004 Sep: 23(9)881-2
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Journal of clinical microbiology , 2004 May: 42(5)1915-22
Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).
The Journal of clinical investigation , 2004 Feb: 113(3)464-73
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
American journal of respiratory and critical care medicine , 2003 Dec 15: 168(12)1471-5
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
Environmental microbiology , 2003 Dec: 5(12)1341-9
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , 2003 Oct 1: 290(13)1749-56
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
Journal of clinical microbiology , 2003 Sep: 41(9)4312-7
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest , 2003 May: 123(5)1495-502
Cepacia-like syndrome caused by Burkholderia multivorans.
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses , March 2003: 14(2)123-5
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , 2003 Mar 15: 167(6)841-9
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa
J Bacteriol , Feb. 2003: 1316-25
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa.
Journal of bacteriology , Feb. 2003: 185(4)1316-25
Cepacia-like syndrome caused by Burkholderia multivorans.
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses , 2003 Mar: 14(2)123-5
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
Chest , 2003: : 792-9
Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection.
Infection and immunity , 2003: : 1405-15
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Medical and pediatric oncology , 2003: : 93-8
Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Journal of clinical microbiology , Jan. 2003: 492-4
Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Journal of clinical microbiology , Jan. 2003: 41(1)492-4
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
Infection and immunity , March 2002: 1081-6
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
Infection and immunity , March 2002: 70(3)1081-6
Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples.
Journal of clinical microbiology , 2002: : 2791-2794
Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation , 2002: 40: 365-372
Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.
Chest , 2002: 121: 1754-1760
Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.
Journal of clinical microbiology , 2002: : 1210-1213
Ampicillin use in infant fever: a systematic review.
Archives of pediatrics and adolescent medicine , Jan. 2002: 27-32
Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.
Journal of clinical microbiology , 2002: 40: 26-30
Emergence of new pathogens in CF: the devil we know or the devil we don't know?
The Journal of pediatrics , : : 283-4
Pathophysiology and management of pulmonary infections in cystic fibrosis.
American journal of respiratory and critical care medicine , : : 918-51
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
Thorax , : : 360-7
Anti-inflammatory properties of macrolides.
The Pediatric infectious disease journal , : : 75-6

Presentations

Presentations TitleEventLocationDate
Newest evidence for management of pediatric urinary tract infectionsNorth Pacific Pediatric Society 183rd Scientific ConferenceCoeur d’Alene, IDAug. 2011
Small colony variants in CF: Watch out for the little guysNW ASM Branch MeetingSeattle, WAOct. 2010
Understanding the clinical microbiology labNACFCBaltimore, MDOct. 2010
The red queen: A history of infectious diseaseNorth Pacific Pediatric Society 180th Scientific ConferenceSeattle, WAMarch 2010
Unique problems in cystic fibrosis microbiologyNorthwest Medical Laboratory Symposium (NWMLS)Seattle, WAOct. 1, 2009
Molecular diagnostics in cystic fibrosis microbiologySymposium on Respiratory Infections, Novel Research Exploring Diagnosis and Management - SickKids Research InstituteToronto, Ontario, CanadaSept. 1, 2009
Diagnosis and management of cystic fibrosis airway infectionsGrand Rounds, Hospital for Sick ChildrenToronto, Ontario, CanadaSept. 1, 2009
Pathogenesis of cystic fibrosis lung infections, important pathogensKarolinska Universitetssjukhuset CF RegionstudiedagStockholm, SwedenMay 1, 2009
Antibiotic susceptibility testing in CFUppsala UniversitetStockholm, SwedenMay 1, 2009
CF airway infections - Opponent for Ph.D. dissertation, Elin NilssonUppsala UniversitetStockholm, SwedenMay 1, 2009
Hypermutability of B. cenocepacia in CFInternational Burkholderia cepacia Working Group (IBCWG)Toronto, CanadaApril 1, 2009
Challenging the paradigm: novel susceptibility testing methods for CFNorth Killarney National Cystic Fibrosis MeetingKillarney, IrelandJan. 2, 2009

Research Funding

Grant TitleGrantorAmountAward Date
Prevalence and Clinical Significance of S. aureus small-colony variants - HOFFMA14A0 (PI: Burns and Hoffman)Cystic Fibrosis Foundation Therapeutics $109,481 Burns annual direct costsApril 1, 2014 - March 31, 2017
Long Term Outcomes after Eradication of Pseudomonas aeruginosa among Children Enrolled in the EPIC Clinical Trial - #CTBM100CUSNC01T (PI: Hamblett)Novartis $34,426 annual direct costsDec. 15, 2013 - Dec. 15, 2015
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis - UM1 HL119073 (PI: Goss) $, $55,495 Burns' annual direct costsSept. 1, 2013 - June 30, 2016
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Repeat-Dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosaKaloBios Pharmaceuticals, Inc. $45,032 total direct costsOct. 10, 2012 - Oct. 9, 2014
Lab Services - Grifols Protocol# T6005-201Grifols Therapeutics, Inc.April 10, 2012 - April 10, 2014
Persistent MRSA Eradication Protocol - #PMEP11K1 (PI: Dasenbrook)CFFT $37,240 subcontract annual direct costsJan. 1, 2012 - Dec. 31, 2014
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis - P30 DK089507 (PI: Ramsey & Greenberg)NIH $25,749 Burns' annual direct costsJuly 6, 2010 - May 31, 2015
Safety and efficacy of aztreonamGilead SciencesJan. 12, 2010 - Jan. 12, 2015
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatmentNIH $, $Sept. 11, 2009 - July 31, 2014
Therapeutics Development Network Coordinating Center (CFFT Infrastructure 2014-2015) (PI: Ramsey)CFFT $11,443 Burns' annual direct costsApril 1, 2004 - March 31, 2015
Translational Therapeutics Development Center - #GIBSON09YO (PI: Gibson)Cystic Fibrosis Foundation Therapeutics $166,400 annual direct costsApril 1, 2004 - Dec. 31, 2014
Therapeutic Development Center Microbiology Core Laboratory - #BURNS03Y3Cystic Fibrosis Foundation Therapeutics $112,315 annual direct costsApril 1, 2003 - Dec. 31, 2014

Primary Office

Seattle Children's Research Institute
JMB - 8 - Infectious Disease
1900 - 9th Ave
Seattle, WA 98101
206-987-2073

Additional Offices

Seattle Children's
MA.7.226 - Infectious Disease Clinic
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2073

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options